Fundraising Fox

Tribune Therapeutics AB

Founded 2020 · 3 known investors

tribunetx.com ↗

Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways. Its lead candidate, TRX-44, aims to treat fibrotic diseases affecting organs such as the lungs and kidneys regardless of cause.

BiotechHealthtech

Founders & leadership

Tribune Therapeutics AB was founded in 2020 by Ole Kaasbøll.

OK
Ole KaasbøllCo-founder

Investors · 3

HealthCap✓ verifiedStockholm
IndustrifondenStockholm · $1.1M – $4.3M
LifeArc VenturesLondon

In the news

Innovestor Life Science fund invests in Tribune Therapeutics - Pääomasijoittajatpaaomasijoittajat.fi · Mar 2025Tribune Therapeutics Raises EUR 37 Million for Next-Generation Anti-Fibrotic Therapies - BioSpacebiospace.com · Mar 2025Swedish biotech startup Tribune Therapeutics raises €37M in fresh fundingen.ain.ua · Mar 2025Tribune Therapeutics Raises EUR 37M in Seed and Series A Fundingfinsmes.com · Mar 2025Tribune Therapeutics Raises EUR 37 Million for Next-Generation Anti-Fibrotic Therapiesbusinesswire.com · Mar 2025

Frequently asked questions

What does Tribune Therapeutics AB do?
Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines that target CCN protein family signaling (such as CCN2/CTGF) to block fibrotic pathways. Its lead candidate, TRX-44, aims to treat fibrotic diseases affecting organs such as the lungs and kidneys regardless of cause.
Who founded Tribune Therapeutics AB?
Tribune Therapeutics AB was founded by Ole Kaasbøll in 2020.
Who are Tribune Therapeutics AB's investors?
Tribune Therapeutics AB's investors include HealthCap, Industrifonden, LifeArc Ventures.